Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 8/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14613477 | 0.91 | KCNK3 (0.42) | KCNK3KCNK9PARP1GSK3BHPGD | |
| SCHEMBL12953809 | 0.85 | RAB9A (0.43) | KCNK3KCNK9GSK3BMEN1NPC1 | |
| SCHEMBL12953974 | 0.85 | SIRT2 (0.40) | GSK3BCDK2CCNE1MEN1KMT2A | |
| SCHEMBL12954353 | 0.85 | DDR2 (0.47) | KCNK3KCNK9MEN1RAB9AKMT2A | |
| SCHEMBL13119623 | 0.83 | CDK2 (0.59) | GSK3BCDK2CCNE1 | |
| SCHEMBL13305578 | 0.83 | GSK3B (0.47) | GSK3BCDK2MEN1NPC1RAB9A | |
| SCHEMBL14301781 | 0.82 | RET (0.46) | GSK3BCDK2MEN1NPC1RAB9A | |
| SCHEMBL12954361 | 0.80 | GSK3B (0.42) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL14613482 | 0.79 | GSK3B (0.42) | GSK3BCDK2CCNE1MEN1KMT2A | |
| SCHEMBL14043168 | 0.78 | KMT2A (0.46) | GSK3BCDK2CCNE1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | KCNK3 1754/4885KCNK9 1948/4885PARP1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.